The DOI matches its Crossref record; the references it cites are not checked yet.
Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1‐FV in a randomized controlled trial
Open accessAbstract
Background: Pollen extracts and chemically modified allergoids are used successfully in allergen immunotherapy (AIT). Recombinant extracts offer potential advantages with respect to pharmaceutical quality, standardization and dosing. A hypoallergenic recombinant folding variant of the major birch pollen allergen (rBet v 1‐FV) was compared with an established native birch preparation. A pre‐seasonal, randomized, actively controlled phase II study was performed in birch pollen allergic rhino‐conjunctivitis with or without asthma, GINA I/ II. 51 patients (24 rBet v 1‐FV, 27 native extract) started therapy with subcutaneous allergen immunotherapy (SCIT). Primary end‐point was a combined symptom medication score (SMS), changes in nasal provocation test, visual rating score and specific antibody responses secondary end‐points. Findings: After one pre‐seasonal treatment course the combined SMS was 5.86 (median; IQR: 14.02) for the rBet v 1‐FV group versus 12.40 (median; IQR: 9.32) for the comparator during the three weeks pollen season (p = 0.330). After treatment in the second year, scores were 3.00 (median; IQR: 6.50) and 2.93 (4.86) respectively. Allergen tolerance in a nasal provocation test improved to a comparable extent in both groups. Significant increases in birch pollen‐specific IgG1 and IgG4 were observed in both treatment groups following the first treatment phase and remained significantly raised until the end of the study. Conclusion: In this first in man, proof of concept phase II trial no statistical difference between rBet v 1‐FV and an established natural pollen extract could be observed. rBet v 1‐FV could be administered in higher doses than the native protein with no increase in adverse effects. Trial registration: The study was registered in ClinicalTrials.gov (NCT00266526).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“If conjunctivitis is to be assessed simultaneously with rhinitis symptoms, then the Rhinitis Total Symptom Score (RTSS) can be combined with Rescue Medication Score (RMS) to yield the combined score (CS).805”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [805]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 11 · Cited by 54
Research works printed but not linked: 1
- European Medicines Agency, 2002, ICH Topic E6 (R1). Guideline for Good Clinical Practice. Step 5. Note for Guidance on Good Clinical Practice
Metadata
- Authors
- Klimek, L., Bachert, C., Lukat, K., Pfaar, O., Meyer, H., & Narkus, A.
- Affiliations
- Zentrum für Rhinologie und Allergologie (DE)
- Ghent University Hospital (BE)
- Respiratory Research Institute (DE)
- Allergopharma GmbH & Co. KG (Germany) (DE)
- Corresponding author
- Klimek, Ludger
- Venue
- Clinical and Translational Allergy
- Publisher
- Wiley
- Published
- 2015-01
- Volume
- 5
- Issue
- 1
- Pages
- 28-28
- ISSN
- 2045-7022 (ISSN-L)
- PMC
- PMC4553934
- OpenAlex
- W1925419919
- Cited by
- 54
- References
- 11
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 6 · 2021: 6 · 2020: 6 · 2019: 7 · 2018: 10 · 2017: 3 · 2016: 4 · 2015: 1
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical and Translational Allergy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- European Academy of Allergy and Clinical Immunology
- Allergopharma
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- allergen immunotherapy, subcutaneous allergen immunotherapy, birch pollen allergy, allergic rhinoconjunctivitis, asthma, nasal provocation test, allergen tolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1‐FV in a randomized controlled trial. https://app.cochat.ai/papers/10.1186/s13601-015-0071-x
- The paper
- Klimek, L., Bachert, C., Lukat, K., Pfaar, O., Meyer, H., & Narkus, A. (2015). Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1‐FV in a randomized controlled trial. Clinical and Translational Allergy. https://doi.org/10.1186/s13601-015-0071-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.